Log in

RKV Rakovina Therapeutics Inc TSXV · Canada

Rakovina Therapeutics (RKV) news

Rakovina Therapeutics Inc is a public biotech or pharmaceutical company listed on TSXV under the ticker RKV, recorded under Canada. The directory classifies it as Oncology drug developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Rakovina Therapeutics news

We have not published a story on Rakovina Therapeutics yet. When there is news, it will appear here.

Questions about Rakovina Therapeutics

What is the ticker symbol of Rakovina Therapeutics?

Rakovina Therapeutics Inc trades under the ticker RKV on TSXV.

Where is Rakovina Therapeutics listed?

Rakovina Therapeutics Inc is listed on TSXV.

Which country or territory is Rakovina Therapeutics listed under?

Our directory records Rakovina Therapeutics Inc under Canada.

What does Rakovina Therapeutics do?

Our directory classifies Rakovina Therapeutics Inc as: Oncology drug developer. This is a directory classification, not a description of the pipeline.

What is the ISIN of Rakovina Therapeutics?

The ISIN recorded for Rakovina Therapeutics Inc is CA75103L3092.

Does aibio.space cover Rakovina Therapeutics?

aibio.space lists Rakovina Therapeutics Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Rakovina Therapeutics?

Companies in our directory listed in the same country and business area as Rakovina Therapeutics: InnoCan Pharma, Apotex Health, Thiogenesis Therapeutics, Simply Solventless Concentrates, BetterLife Pharma, InMed Pharmaceuticals.

Investor discussion: Rakovina Therapeutics

Members talk about Rakovina Therapeutics (RKV). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TSXV:RKV on TradingView.

Listing details

Rakovina Therapeutics Inc is a public biotech or pharmaceutical company listed on TSXV under the ticker RKV, recorded under Canada. The directory classifies it as Oncology drug developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Rakovina Therapeutics Inc
Ticker
RKV
Listing
TSXV
Country or territory
Canada
Business scope
Oncology drug developer
ISIN
CA75103L3092
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.